Targeting tumor suppressor gene co‐mutations in EGFR ‐mutant nonsmall cell lung cancer: How ACROSS2 sharpens the case for early intensification
CA: A Cancer Journal for Clinicians · 2026-03 · 76 (2)
DOI: 10.3322/caac.70072 ↗Kurz gefasst
Editorial in der Zeitschrift CA: A Cancer Journal for Clinicians, online erschienen am 12.03.2026. Verfasst von Krishna S Gunturu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Hartford HealthCare Cancer Institute, Hartford, Connecticut, USA. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Hartford HealthCare Cancer Institute, Hartford, Connecticut, USA.
- The Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.
- Sylvester Comprehensive Cancer Center at the University of Miami and the Miller School of Medicine, Miami, Florida, USA.
ORCID-Profile: Hina Khan, Gilberto de Lima Lopes
Zitieren
APA
Gunturu, K. S., Khan, H., & de Lima Lopes, G. (2026). Targeting tumor suppressor gene co‐mutations in EGFR ‐mutant nonsmall cell lung cancer: How ACROSS2 sharpens the case for early intensification. CA: A Cancer Journal for Clinicians, 76(2). https://doi.org/10.3322/caac.70072
Vancouver
Gunturu KS, Khan H, de Lima Lopes G. Targeting tumor suppressor gene co‐mutations in EGFR ‐mutant nonsmall cell lung cancer: How ACROSS2 sharpens the case for early intensification. CA: A Cancer Journal for Clinicians. 2026;76(2). doi:10.3322/caac.70072
BibTeX
@article{Gunturu2026,
author = {Gunturu, Krishna S and Khan, Hina and de Lima Lopes, Gilberto},
title = {Targeting tumor suppressor gene co‐mutations in EGFR ‐mutant nonsmall cell lung cancer: How ACROSS2 sharpens the case for early intensification},
journal = {CA: A Cancer Journal for Clinicians},
year = {2026},
volume = {76},
number = {2},
doi = {10.3322/caac.70072}
}
EUVIMED